Relmada Therapeutics Inc. (RLMD)
$4.46
$0.10
(2.29%)
As on 01-Sep-2026 16:00EDT
Market cap
$462 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.9
-
Face value
--
-
Shares outstanding
106,669,846
10 Years Aggregate
CFO
$-524.38 Mln
EBITDA
$-834.79 Mln
Net Profit
$-787.81 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Relmada Therapeutics (RLMD)
| -7.7 | -16.0 | -38.1 | 298.2 | 9.7 | -28.5 | -1.7 |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Relmada Therapeutics (RLMD)
| 828.8 | -87.2 | 18.6 | -84.5 | -29.7 | -17.8 | 747.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Relmada Therapeutics (RLMD)
|
4.5 | 461.9 | 0.0 | -61.9 | -- | -42.3 | -- | 2.3 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 260.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Relmada Therapeutics (RLMD)
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2... clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida. Read more
-
CEO & Director
Dr. Sergio Traversa M.B.A., Pharm.D.
-
CEO & Director
Dr. Sergio Traversa M.B.A., Pharm.D.
-
Headquarters
Coral Gables, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Relmada Therapeutics (RLMD)
What is the current share price of Relmada Therapeutics Inc (RLMD) Today?
The share price of Relmada Therapeutics Inc (RLMD) is $4.46 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Relmada Therapeutics Inc (RLMD) has given a return of 9.68% in the last 3 years.
What is the current PB & PE ratio of Relmada Therapeutics Inc (RLMD)?
Since, TTM earnings of Relmada Therapeutics Inc (RLMD) is negative, P/E ratio is not available.
The P/B ratio of Relmada Therapeutics Inc (RLMD) is 2.33 times as on 28-Aug-2026, a 55 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-5.74 |
3.81 |
2024 |
-0.20 |
0.44 |
2023 |
-1.26 |
1.46 |
2022 |
-0.67 |
0.75 |
2022 |
-4.53 |
2.74 |
What is the 52 Week High and Low of Relmada Therapeutics Inc (RLMD)?
The 52-week high and low of Relmada Therapeutics Inc (RLMD) are Rs 8.00 and Rs 1.06 as of 02-Sep-2026.
What is the market cap of Relmada Therapeutics Inc (RLMD)?
Relmada Therapeutics Inc (RLMD) has a market capitalisation of $ 462 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Relmada Therapeutics Inc (RLMD)?
Before investing in Relmada Therapeutics Inc (RLMD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.